Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has just gotten the green light from the U.S. government to sell Verapamil Hydrochloride Extended-Release Tablets. These tablets, available in 120 mg, 180 mg, and 240 mg doses, are a medicine used to lower dangerously high blood pressure. Lowering blood pressure helps prevent serious health issues like heart attacks and strokes.

• Zydus secured USFDA approval for Verapamil Hydrochloride tablets.
• Tablets treat high blood pressure effectively, reducing health risks.
• Dosages are 120mg, 180mg, and 240mg available for patients.
• Production will occur at Zydus Lifesciences’ Baddi facility.
• Annual US sales hit $24.5 million in the last nine months.
• This approval strengthens Zydus’ portfolio in cardiovascular care.

Production Details

The tablets will be made at Zydus Lifesciences’ factory located in Baddi, Himachal Pradesh, India. This means the medicine will be produced locally, which can sometimes make it cheaper and easier to get.

Sales Performance

In the United States, Verapamil Hydrochloride Extended-Release Tablets sold approximately $24.5 million during the most recent nine-month period, as tracked by IQVIA. This shows a significant market interest in the product’s effectiveness.

This approval represents a valuable addition to Zydus’ offerings and a positive step for patients managing cardiovascular health.